Plasmacytoid dendritic cells and M2 macrophages are associated with clinical outcomes in human papillomavirus–independent vulvar squamous cell carcinoma
Abstract
BackgroundVulvar squamous cell carcinoma (VSCC) is a rare malignancy comprising HPV-associated (HPV-A) and HPV-independent (HPV-I) subtypes. HPV-I is associated with high recurrence rates and poor survival, yet lacks validated prognostic biomarkers and therapeutic stratification tools. Although immunotherapy has transformed cancer care and highlighted the tumor microenvironment (TME) as an important determinant of clinical outcome, the rarity of VSCC has limited its molecular characterization, and the TME remains poorly understood. We therefore aimed to define the VSCC TME in an HPV-specific context and identify immune features associated with clinical outcomes.MethodsWe analyzed 70 surgically treated VSCC (18 HPV-A and 52 HPV-I) using targeted transcriptomic profiling (HTG EdgeSeq). Immune and stromal cell composition was inferred by computational deconvolution, primarily with xCell and supported by EPIC, quanTIseq and MCPcounter. TME composition was compared by HPV status and, within HPV-I VSCC, by p53 and PD-L1 immunohistochemical status. Associations with recurrence-free and disease-specific survival were assessed using Firth-penalized Cox regression adjusted for FIGO stage and p53 status, and candidate populations were evaluated by CD123 and CD163 immunohistochemistry.ResultsHPV-A tumors showed higher immune and overall microenvironment scores, with enrichment of diverse lymphoid and myeloid populations, whereas HPV-I tumors showed lower immune-cell enrichment. Within HPV-I VSCC, plasmacytoid dendritic cell (pDC) enrichment showed the most consistent association with favorable survival across deconvolution-based analyses, with immunohistochemistry confirming CD123+ cell infiltration as an independent favorable prognostic factor. PD-L1 positivity occurred in 44% of HPV-I tumors and was associated with CD163+ macrophage infiltration, which, in turn, was independently associated with poor outcomes.ConclusionsTME profiling identified two clinically relevant immune populations within HPV-I VSCC: CD123+ cell infiltration was associated with favorable outcomes, whereas CD163+ macrophage infiltration was associated with PD-L1 positivity and poorer outcomes. These findings provide a rationale for further investigation of the TME as a source of prognostic and potentially therapeutic biomarkers. Validation in larger, independent cohorts is required before clinical utility can be established.
Related
- Unexpected detrimental role of plasmacytoid dendritic cells during viral infections of the lungs
- Circular DNA interacts with Cathelicidin LL37 to efficiently activate plasmacytoid dendritic cells
- BDCA2-dependent phagocytosis enables strain-specific activation of plasmacytoid dendritic cells by lactic acid bacteria
- The plasmacytoid dendritic cell paradox in cancer: impaired type I interferon responses in a nucleic acid–rich tumor microenvironment
- Activation of conventional and plasmacytoid dendritic cells and enhancement of anti-viral immune responses by Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 and Streptococcus thermophilus OLS3059
BibTeX
@article{penuelas2026plasmacytoid,
title = {{Plasmacytoid dendritic cells and M2 macrophages are associated with clinical outcomes in human papillomavirus–independent vulvar squamous cell carcinoma}},
author = {Núria Peñuelas and Lia Sisuashvili and Lorena Marimón and Laia Díez-Ahijado and Núria Carreras-Dieguez and Clement Gonzalez-Serra and Katarzyna Darecka and Juan Muñoz-Hurtado and Adela Saco and Marta del Pino and Aureli Torné and Silvia Valls-Losada and Anna Escoda-Suarez and Beatriz Sánchez-Hoyo and Lydia Gaba and Jaume Ordi and Robert Albero and Natalia Rakislova},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1922286},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1922286},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Plasmacytoid dendritic cells and M2 macrophages are associated with clinical outcomes in human papillomavirus–independent vulvar squamous cell carcinoma
AU - Núria Peñuelas
AU - Lia Sisuashvili
AU - Lorena Marimón
AU - Laia Díez-Ahijado
AU - Núria Carreras-Dieguez
AU - Clement Gonzalez-Serra
AU - Katarzyna Darecka
AU - Juan Muñoz-Hurtado
AU - Adela Saco
AU - Marta del Pino
AU - Aureli Torné
AU - Silvia Valls-Losada
AU - Anna Escoda-Suarez
AU - Beatriz Sánchez-Hoyo
AU - Lydia Gaba
AU - Jaume Ordi
AU - Robert Albero
AU - Natalia Rakislova
PY - 2026
DA - 2026/11/06
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1922286
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1922286
AB - BackgroundVulvar squamous cell carcinoma (VSCC) is a rare malignancy comprising HPV-associated (HPV-A) and HPV-independent (HPV-I) subtypes. HPV-I is associated with high recurrence rates and poor survival, yet lacks validated prognostic biomarkers and therapeutic stratification tools. Although immunotherapy has transformed cancer care and highlighted the tumor microenvironment (TME) as an important determinant of clinical outcome, the rarity of VSCC has limited its molecular characterization, and the TME remains poorly understood. We therefore aimed to define the VSCC TME in an HPV-specific context and identify immune features associated with clinical outcomes.MethodsWe analyzed 70 surgically treated VSCC (18 HPV-A and 52 HPV-I) using targeted transcriptomic profiling (HTG EdgeSeq). Immune and stromal cell composition was inferred by computational deconvolution, primarily with xCell and supported by EPIC, quanTIseq and MCPcounter. TME composition was compared by HPV status and, within HPV-I VSCC, by p53 and PD-L1 immunohistochemical status. Associations with recurrence-free and disease-specific survival were assessed using Firth-penalized Cox regression adjusted for FIGO stage and p53 status, and candidate populations were evaluated by CD123 and CD163 immunohistochemistry.ResultsHPV-A tumors showed higher immune and overall microenvironment scores, with enrichment of diverse lymphoid and myeloid populations, whereas HPV-I tumors showed lower immune-cell enrichment. Within HPV-I VSCC, plasmacytoid dendritic cell (pDC) enrichment showed the most consistent association with favorable survival across deconvolution-based analyses, with immunohistochemistry confirming CD123+ cell infiltration as an independent favorable prognostic factor. PD-L1 positivity occurred in 44% of HPV-I tumors and was associated with CD163+ macrophage infiltration, which, in turn, was independently associated with poor outcomes.ConclusionsTME profiling identified two clinically relevant immune populations within HPV-I VSCC: CD123+ cell infiltration was associated with favorable outcomes, whereas CD163+ macrophage infiltration was associated with PD-L1 positivity and poorer outcomes. These findings provide a rationale for further investigation of the TME as a source of prognostic and potentially therapeutic biomarkers. Validation in larger, independent cohorts is required before clinical utility can be established.
SN - 1664-3224
ER -